Survivors of Hodgkin Lymphoma (HL) have significantly elevated long-term risks of cardiovascular disease (CVD), substantially attributable to prior treatment with radiotherapy and anthracycline-based chemotherapy. In the GRACE-HL Study, funded by KWF, we are characterising the germline genetic factors that influence the risks of radiation- and anthracycline-associated CVD for survivors of HL in the Netherlands. With this research, we will better understand which HL survivors have elevated and reduced risks of CVD to inform personalised cardiovascular surveillance.
